CL2016002577A1 - Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares. - Google Patents

Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares.

Info

Publication number
CL2016002577A1
CL2016002577A1 CL2016002577A CL2016002577A CL2016002577A1 CL 2016002577 A1 CL2016002577 A1 CL 2016002577A1 CL 2016002577 A CL2016002577 A CL 2016002577A CL 2016002577 A CL2016002577 A CL 2016002577A CL 2016002577 A1 CL2016002577 A1 CL 2016002577A1
Authority
CL
Chile
Prior art keywords
pharmacological
benzodioxadiazacyclooctadecino
azeno
methene
prophylaxis
Prior art date
Application number
CL2016002577A
Other languages
English (en)
Inventor
Philip Lienau
Ulrich Lücking
Pierre Wasnaire
Arne Scholz
Gerhard Siemeister
Christian Stegmann
Ulf Bömer
Kunzeng Zheng
Ping Gao
Gang Chen
Jiajun Xi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016002577A1 publication Critical patent/CL2016002577A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos macrólidos derivados de 3,4-2H,11H-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares.
CL2016002577A 2014-04-11 2016-10-11 Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares. CL2016002577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014000392 2014-04-11

Publications (1)

Publication Number Publication Date
CL2016002577A1 true CL2016002577A1 (es) 2017-04-07

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002577A CL2016002577A1 (es) 2014-04-11 2016-10-11 Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares.

Country Status (28)

Country Link
US (1) US9963464B2 (es)
EP (1) EP3129387B1 (es)
JP (1) JP6605493B2 (es)
KR (1) KR102383938B1 (es)
CN (1) CN106459084B (es)
AP (1) AP2016009483A0 (es)
AR (1) AR099999A1 (es)
AU (1) AU2015243585B2 (es)
BR (1) BR112016023554B1 (es)
CA (1) CA2945237C (es)
CL (1) CL2016002577A1 (es)
CR (1) CR20160471A (es)
CU (1) CU24399B1 (es)
DO (1) DOP2016000278A (es)
EA (1) EA032541B1 (es)
ES (1) ES2743799T3 (es)
IL (1) IL247966B (es)
MX (1) MX2016013362A (es)
PE (1) PE20161379A1 (es)
PH (1) PH12016501968A1 (es)
SG (1) SG11201608430RA (es)
SV (1) SV2016005301A (es)
TN (1) TN2016000435A1 (es)
TW (1) TW201623312A (es)
UA (1) UA119349C2 (es)
UY (1) UY36072A (es)
WO (1) WO2015155197A1 (es)
ZA (1) ZA201607765B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290903B (zh) * 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
CN108368129B (zh) * 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
PT3445767T (pt) * 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
RU2019111887A (ru) * 2016-10-20 2020-11-20 Пфайзер Инк. Антипролиферативные средства для лечения лаг
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
KR20070091018A (ko) 2004-12-17 2007-09-06 아스트라제네카 아베 Ｃｄｋ 억제제로서의4-(4-(이미다졸-4-일)피리미딘-2-일아미노)벤즈아미드
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
KR20090101905A (ko) 2006-12-22 2009-09-29 노파르티스 아게 인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
JP5566880B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
AU2011231975B2 (en) 2010-03-22 2014-07-03 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN103562184B (zh) 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
WO2013037896A1 (en) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
CN104918918B (zh) 2012-11-15 2017-10-24 拜耳药业股份公司 含磺亚胺基团的4‑(邻)‑氟苯基‑5‑氟嘧啶‑2‑基胺
LT2928878T (lt) 2012-11-15 2016-11-25 Bayer Pharma Aktiengesellschaft 5-fluor-n-(piridin-2-il)piridin-2-amino dariniai, turintys sulfoksimino grupę
WO2015001021A1 (en) 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
EP3129387B1 (en) 2019-06-26
UA119349C2 (uk) 2019-06-10
AU2015243585B2 (en) 2019-08-01
CR20160471A (es) 2016-12-21
CU20160152A7 (es) 2017-04-05
CA2945237C (en) 2022-09-06
KR20160136449A (ko) 2016-11-29
UY36072A (es) 2015-11-30
CA2945237A1 (en) 2015-10-15
WO2015155197A1 (en) 2015-10-15
ZA201607765B (en) 2022-09-28
MX2016013362A (es) 2017-02-09
CN106459084A (zh) 2017-02-22
JP2017510598A (ja) 2017-04-13
EA032541B1 (ru) 2019-06-28
AU2015243585A1 (en) 2016-10-13
AR099999A1 (es) 2016-08-31
CU24399B1 (es) 2019-04-04
SG11201608430RA (en) 2016-11-29
BR112016023554A2 (pt) 2017-08-15
PH12016501968A1 (en) 2016-12-19
KR102383938B1 (ko) 2022-04-08
TW201623312A (zh) 2016-07-01
ES2743799T3 (es) 2020-02-20
PE20161379A1 (es) 2017-01-15
BR112016023554B1 (pt) 2023-03-14
US9963464B2 (en) 2018-05-08
TN2016000435A1 (en) 2018-04-04
US20170029439A1 (en) 2017-02-02
IL247966B (en) 2021-02-28
JP6605493B2 (ja) 2019-11-13
AP2016009483A0 (en) 2016-10-31
DOP2016000278A (es) 2016-11-15
SV2016005301A (es) 2018-03-12
EA201692034A1 (ru) 2017-04-28
CN106459084B (zh) 2019-04-19
EP3129387A1 (en) 2017-02-15
IL247966A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CL2016002577A1 (es) Compuestos macrólidos derivados de 3,4-2h,11h-10,6-(azeno)-12,16-(meteno)-1,5,11,13-benzodioxadiazaciclooctadecino; compuestos intermediarios, sin acción farmacológica; procedimiento de preparación; composiciones y combinaciones farmacológicas; útiles para el tratamiento y/o profilaxis de trastornos hiperproliferativo, enfermedades infecciosas inducidas por virus y/o enfermedades cardiovasculares.
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1256904B (zh) 用於預防或治療艾滋病病毒感染的治療用化合物
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
PH12017500207B1 (en) Indoles for use in influenza virus infection
WO2016099982A3 (en) Phosphoramidates for the treatment of hepatitis b virus
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
CL2017000151A1 (es) Derivados de piridona
BR112016023833A2 (pt) compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
TW201611845A (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection